Endevica Bio

Endevica Bio develops first-in-class peptide therapeutics using proprietary peptidomimetic technology. Its lead candidate, TCMCB07, a melanocortin receptor antagonist peptide, has shown positive safety results in Phase 1 trials and will enter a pivotal Phase 2 trial in patients with stage IV metastatic colorectal cancer to prevent chemotherapy-induced weight loss. The company also has preclinical programs targeting obesity and metabolic disorders with promising animal efficacy data showing weight loss without typical GLP‑1 side effects. The technology enables modulation of key CNS drug targets by crossing the blood-brain barrier safely and effectively.